Krüppel-like factor 4 blocks tumor cell proliferation and promotes drug resistance in multiple myeloma

Haematologica

Volumn 98, Issue 9, 2013, Pages 1442-1449

  Schoenhals, Matthieu ^a   Kassambara, Alboukadel ^a   Veyrune, Jean Luc ^a,b   Moreaux, Jerome ^a,b   Goldschmidt, Hartmut ^c   Hose, Dirk ^c   Klein, Bernard ^a,b,d  

^a INSERM   (France)

^b MONTPELLIER UNIVERSITY HOSPITAL   (France)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^d UNIV MONTPELLIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; BORTEZOMIB; CELL CYCLE PROTEIN; DOXYCYCLINE; KRUPPEL LIKE FACTOR 4; MELPHALAN; PROTEIN P53;

ARTICLE; CELL CYCLE ARREST; CELL DEATH; CELL PROLIFERATION; CHROMOSOME TRANSLOCATION; CONTROLLED STUDY; DNA METHYLATION; EPIGENETICS; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; MONOCYTE; MULTIPLE MYELOMA; POLYMERASE CHAIN REACTION; PYROSEQUENCING; STEM CELL TRANSPLANTATION; WESTERN BLOTTING;

AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; KRUPPEL-LIKE TRANSCRIPTION FACTORS; MALE; MULTIPLE MYELOMA;

EID: 84883643294     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2012.066944     Document Type: Article

References (44)

1. Evans PM, Liu C. Roles of Krupel-like factor 4 in normal homeostasis, cancer and stem cells. Acta Biochim Biophys Sin (Shanghai). 2008;40(7):554-64.
2. Katz JP, Perreault N, Goldstein BG, Lee CS, Labosky PA, Yang VW, et al. The zinc-finger transcription factor Klf4 is required for terminal differentiation of goblet cells in the colon. Development. 2002;129(11): 2619-28.
3. Kharas MG, Yusuf I, Scarfone VM, Yang VW, Segre JA, Huettner CS, et al. KLF4 suppresses transformation of pre-B cells by ABL oncogenes. Blood. 2006;109(2):747-55.
4. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663-76.
5. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007; 131(5):861-72.
6. Wei Z, Yang Y, Zhang P, Andrianakos R, Hasegawa K, Lyu J, et al. Klf4 interacts directly with Oct4 and Sox2 to promote reprogramming. Stem Cells. 2009;27(12): 2969-78.
7. Rowland BD, Peeper DS. KLF4, p21 and context-dependent opposing forces in cancer. Nat Rev Cancer. 2005;6(1):11-23.
8. Rowland BD, Bernards R, Peeper DS. The KLF4 tumour suppressor is a transcriptional repressor of p53 that acts as a contextdependent oncogene. Nat Cell Biol. 2005;7 (11):1074-82.
9. Zhang W, Geiman DE, Shields JM, Dang DT, Mahatan CS, Kaestner KH, et al. The gut-enriched Kruppel-like factor (Kruppellike factor 4) mediates the transactivating effect of p53 on the p21WAF1/Cip1 promoter. J Biol Chem. 2000;275(24):18391-8.
10. Wei D, Kanai M, Jia Z, Le X, Xie K. Kruppel-like factor 4 induces p27Kip1 expression in and suppresses the growth and metastasis of human pancreatic cancer cells. Cancer Res. 2008;68(12):4631-9.
11. Zhou Q, Hong Y, Zhan Q, Shen Y, Liu Z. Role for Kruppel-like factor 4 in determining the outcome of p53 response to DNA damage. Cancer Res. 2009;69(21): 8284-92.
12. Guan H, Xie L, Leithauser F, Flossbach L, Moller P, Wirth T, et al. KLF4 is a tumor suppressor in B-cell non-Hodgkin lymphoma and in classical Hodgkin lymphoma. Blood. 2010;116(9):1469-78.
13. Good KL, Tangye SG. Decreased expression of Kruppel-like factors in memory B cells induces the rapid response typical of secondary antibody responses. Proc Natl Acad Sci USA. 2007;104(33):13420-5.
14. Klaewsongkram J, Yang Y, Golech S, Katz J, Kaestner KH, Weng NP. Kruppel-like factor 4 regulates B cell number and activationinduced B cell proliferation. J Immunol. 2007;179(7):4679-84.
15. Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, et al. The molecular classification of multiple myeloma. Blood. 2006;108(6):2020-8.
16. Zhang XG, Gaillard JP, Robillard N, Lu ZY, Gu ZJ, Jourdan M, et al. Reproducible obtaining of human myeloma cell lines as a model for tumor stem cell study in human multiple myeloma. Blood. 1994;83(12): 3654-63.
17. Gu ZJ, Vos JD, Rebouissou C, Jourdan M, Zhang XG, Rossi JF, et al. Agonist antigp130 transducer monoclonal antibodies are human myeloma cell survival and growth factors. Leukemia. 2000;14(1):188-97.
18. Rebouissou C, Wijdenes J, Autissier P, Tarte K, Costes V, Liautard J, et al. A gp130 interleukin-6 transducer-dependent SCID model of human multiple myeloma. Blood. 1998;91(12):4727-37.
19. Moreaux J, Klein B, Bataille R, Descamps G, Maiga S, Hose D, et al. A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines. Haematologica. 2011;96(4):574-82.
20. De Vos J, Thykjaer T, Tarte K, Ensslen M, Raynaud P, Requirand G, et al. Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays. Oncogene. 2002;21 (44):6848-57.
21. Cremer FW, Bila J, Buck I, Kartal M, Hose D, Ittrich C, et al. Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics. Genes Chromosomes Cancer. 2005;44(2):194-203.
22. Barlogie B, Tricot G, Rasmussen E, Anaissie E, van Rhee F, Zangari M, et al. Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies. Blood. 2006;107(7):2633-8.
23. Moreaux J, Cremer FW, Reme T, Raab M, Mahtouk K, Kaukel P, et al. The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. Blood. 2005;106(3):1021-30.
24. Hose D, Moreaux J, Meissner T, Seckinger A, Goldschmidt H, Benner A, et al. Induction of angiogenesis by normal and malignant plasma cells. Blood. 2009;114(1): 128-43.
25. Jourdan M, Caraux A, De Vos J, Fiol G, Larroque M, Cognot C, et al. An in vitro model of differentiation of memory B cells into plasmablasts and plasma cells including detailed phenotypic and molecular characterization. Blood. 2009;114(25): 5173-81.
26. Kassambara A, Hose D, Moreaux J, Walker BA, Protopopov A, Rème T, et al. Genes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myeloma. Haematologica. 2012;97(4):622-30.
27. Jourdan M, Mahtouk K, Veyrune JL, Couderc G, Fiol G, Redal N, et al. Delineation of the roles of paracrine and autocrine interleukin-6 (IL-6) in myeloma cell lines in survival versus cell cycle. A possible model for the cooperation of myeloma cell growth factors. Eur Cytokine Netw. 2005;16(1):57-64.
28. Reme T, Hose D, De Vos J, Vassal A, Poulain PO, Pantesco V, et al. A new method for class prediction based on signed-rank algorithms applied to Affymetrix microarray experiments. BMC Bioinformatics. 2008;9:16.
29. Le Carrour T, Assou S, Tondeur S, Lhermitte L, Lamb N, Rème T, et al. Amazonia!: An online resource to google and visualize public human whole genome expression data. The Open Bioinformatics Journal. 2010;(4):5-10.
30. Cui X, Churchill GA. Statistical tests for differential expression in cDNA microarray experiments. Genome Biol. 2003;4(4):210.
31. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA. 1998;95(25):14863-8.
32. Hose D, Reme T, Hielscher T, Moreaux J, Messner T, Seckinger A, et al. Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma. Haematologica. 2010;96(1):87-95.
33. Walker BA, Leone PE, Jenner MW, Li C, Gonzalez D, Johnson DC, et al. Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma. Blood. 2006;108(5):1733-43.
34. Zhao W, Hisamuddin IM, Nandan MO, Babbin BA, Lamb NE, Yang VW. Identification of Kruppel-like factor 4 as a potential tumor suppressor gene in colorectal cancer. Oncogene. 2004;23(2):395-402.
35. Kee HJ, Kook H. Krüppel-like factor 4 mediates histone deacetylase inhibitorinduced prevention of cardiac hypertrophy. J Mol Cell Cardiol. 2009;47(6):770-80.
36. Kassambara A, Hose D, Moreaux J, Rème T, Torrent J, Rossi JF, et al. Identification of pluripotent and adult stem cell genes unrelated to cell cycle and associated with poor prognosis in multiple myeloma. PLoS ONE. 2012;7(7):e42161.
37. Pei H, Zhang L, Luo K, Qin Y, Chesi M, Fei F, et al. MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites. Nature. 2011;470 (7332):124-8.
38. Asangani IA, Ateeq B, Cao Q, Dodson L, Pandhi M, Kunju LP, et al. Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer. Mol Cell. 2013;49(1):80-93.
39. Muniandy PA, Liu J, Majumdar A, Liu S-T, Seidman MM. DNA interstrand crosslink repair in mammalian cells: step by step. Crit Rev Biochem Mol Biol. 2010;45(1): 23-49.
40. Deans AJ, West SC. DNA interstrand crosslink repair and cancer. Nat Rev Cancer. 2011;11(7):467-80.
41. Ohnishi SS, Ohnami SS, Laub FF, Aoki KK, Suzuki KK, Kanai YY, et al. Downregulation and growth inhibitory effect of epithelial-type Krüppel-like transcription factor KLF4, but not KLF5, in bladder cancer. Biochem Biophys Res. Commun. 2003;308(2):251-6.
42. Jowsey PA, Williams FM, Blain PG. DNA damage responses in cells exposed to sulphur mustard. Toxicol Lett. 2012;209(1):1-10.
43. Voorhees PM, Orlowski RZ. The proteasome and proteasome inhibitors in cancer therapy. Annu Rev Pharmacol Toxicol. 2006;46:189-213.
44. Avet-Loiseau H, Leleu X, Roussel M, Moreau P, Guerin-Charbonnel C, Caillot D, et al. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p). J Clin Oncol. 2010; 28(30):4630-4.